Ciphergen Biosystems Inc.

Report published on biomarkers for early diagnosis of intra-amniotic infection

Published in Physician Law Weekly, September 1st, 2004

Ciphergen Biosystems, Inc., (NASDAQ:CIPH) announced that the SELDI ProteinChip technology was used to discover several biomarkers that showed promising results in the early diagnosis of intra-amniotic infection (IAI), a major cause of preterm birth.

This study, "Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers," which was published in the Journal of American Medical Association (JAMA), also reported that these biomarkers could be detected in serum, suggesting that development of a noninvasive diagnostic test may be possible.

Senior author of the study, Srinivasa R. Nagalla, MD,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2004-09-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry